Status:
RECRUITING
GO TEAM: Glucose Optimization Through Technology Assisted Management
Lead Sponsor:
Sarah MacLeish
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
KeborMed
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
8-18 years
Phase:
NA
Brief Summary
Black/African American children and young adults with type 1 diabetes are less likely to use diabetes technologies, such as continuous glucose monitors, insulin pumps, and automated insulin delivery s...
Eligibility Criteria
Inclusion
- Self-reported as Non-Hispanic Black
- Clinical diagnosis of T1D requiring treatment with insulin at the time of consent
- Not currently (within the past 3 months) using an automated insulin delivery system \\
- Willingness to wear a continuous glucose monitor for 10 days at 3 different time points, and willingness to consider use of a personal continuous glucose monitor
Exclusion
- Clinical diagnosis of Type 2 or monogenic diabetes
- Completed high school
- Non-English speaking guardians
- Automated insulin delivery system use within the past 3 months
- Custody of children and family services
Key Trial Info
Start Date :
January 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 2 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06074458
Start Date
January 29 2024
End Date
November 2 2026
Last Update
July 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106